CONTEXT: Microalbuminuria (albuminuria 30-300 mg per 24-hour urine collection) is a well-known risk marker for arterial thromboembolism. It is assumed that microalbuminuria reflects generalized endothelial dysfunction. Hence, microalbuminuria may also predispose for venous thromboembolism (VTE). OBJECTIVE: To assess whether microalbuminuria is associated with VTE. DESIGN, SETTING, AND PARTICIPANTS: Prevention of Renal and Vascular End-stage Disease (PREVEND) study, an ongoing community-based prospective cohort study initiated in 1997. All inhabitants of Groningen, The Netherlands, aged 28 through 75 years (n = 85,421) were sent a postal questionnaire and a vial to collect a first morning urine sample for measurement of urinary albumin concentration. Of those who responded (40,856), a cohort (8592 participants) including more participants with higher levels of urinary albumin concentration completed screening at an outpatient clinic. Screening data were collected on urinary albumin excretion (UAE) and risk factors for cardiovascular and renal disease. MAIN OUTCOME MEASURE: Symptomatic and objectively verified VTE (ie, deep vein thrombosis, pulmonary embolism, or both) between study initiation and June 1, 2007. RESULTS: Of 8574 evaluable participants (mean [SD] age, 49 [13] years; 50% men), 129 experienced VTE during a mean (SD) follow-up period of 8.6 (1.8) years, corresponding to overall annual incidence of 0.14% (95% confidence interval [CI], 0.11%-0.19%). Annual incidences were 0.12%, 0.20%, 0.40%, and 0.56% in participants with UAE of less than 15 (n = 6013), 15-29 (n = 1283), 30-300 (n = 1144), and greater than 300 (n = 134) mg per 24-hour urine collection, respectively (P for trend <.001). When adjusted for age, cancer, use of oral contraceptives, and atherosclerosis risk factors, hazard ratios associated with UAE levels of 15-29, 30-300, and greater than 300 mg/24 h were 1.40 (95% CI, 0.86-2.35), 2.20 (95% CI, 1.44-3.36), and 2.82 (95% CI, 1.21-6.61), respectively, compared with participants with UAE of less than 15 mg/24 h (global P = .001). Adjusted hazard ratio for microalbuminuria vs normoalbuminuria (UAE <30 mg/24 h) was 2.00 (95% CI, 1.34-2.98; P < .001). Microalbuminuria-related number needed to harm was 388 per year. CONCLUSION: Microalbuminuria is independently associated with an increased risk for VTE.
CONTEXT: Microalbuminuria (albuminuria 30-300 mg per 24-hour urine collection) is a well-known risk marker for arterial thromboembolism. It is assumed that microalbuminuria reflects generalized endothelial dysfunction. Hence, microalbuminuria may also predispose for venous thromboembolism (VTE). OBJECTIVE: To assess whether microalbuminuria is associated with VTE. DESIGN, SETTING, AND PARTICIPANTS: Prevention of Renal and Vascular End-stage Disease (PREVEND) study, an ongoing community-based prospective cohort study initiated in 1997. All inhabitants of Groningen, The Netherlands, aged 28 through 75 years (n = 85,421) were sent a postal questionnaire and a vial to collect a first morning urine sample for measurement of urinary albumin concentration. Of those who responded (40,856), a cohort (8592 participants) including more participants with higher levels of urinary albumin concentration completed screening at an outpatient clinic. Screening data were collected on urinary albumin excretion (UAE) and risk factors for cardiovascular and renal disease. MAIN OUTCOME MEASURE: Symptomatic and objectively verified VTE (ie, deep vein thrombosis, pulmonary embolism, or both) between study initiation and June 1, 2007. RESULTS: Of 8574 evaluable participants (mean [SD] age, 49 [13] years; 50% men), 129 experienced VTE during a mean (SD) follow-up period of 8.6 (1.8) years, corresponding to overall annual incidence of 0.14% (95% confidence interval [CI], 0.11%-0.19%). Annual incidences were 0.12%, 0.20%, 0.40%, and 0.56% in participants with UAE of less than 15 (n = 6013), 15-29 (n = 1283), 30-300 (n = 1144), and greater than 300 (n = 134) mg per 24-hour urine collection, respectively (P for trend <.001). When adjusted for age, cancer, use of oral contraceptives, and atherosclerosis risk factors, hazard ratios associated with UAE levels of 15-29, 30-300, and greater than 300 mg/24 h were 1.40 (95% CI, 0.86-2.35), 2.20 (95% CI, 1.44-3.36), and 2.82 (95% CI, 1.21-6.61), respectively, compared with participants with UAE of less than 15 mg/24 h (global P = .001). Adjusted hazard ratio for microalbuminuria vs normoalbuminuria (UAE <30 mg/24 h) was 2.00 (95% CI, 1.34-2.98; P < .001). Microalbuminuria-related number needed to harm was 388 per year. CONCLUSION: Microalbuminuria is independently associated with an increased risk for VTE.
Authors: Bradley T Endres; Ruben M Sandoval; George J Rhodes; Silvia B Campos-Bilderback; Malgorzata M Kamocka; Christopher McDermott-Roe; Alexander Staruschenko; Bruce A Molitoris; Aron M Geurts; Oleg Palygin Journal: Am J Physiol Renal Physiol Date: 2017-04-12
Authors: Yolanda Hagar; David Albers; Rimma Pivovarov; Herbert Chase; Vanja Dukic; Noémie Elhadad Journal: Stat Anal Data Min Date: 2014-08-19 Impact factor: 1.051
Authors: Caitlin E Carter; Ronald T Gansevoort; Lieneke Scheven; Hiddo J Lambers Heerspink; Michael G Shlipak; Paul E de Jong; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2012-03-01 Impact factor: 8.237
Authors: Elizabeth J Bell; Aaron R Folsom; Pamela L Lutsey; Elizabeth Selvin; Neil A Zakai; Mary Cushman; Alvaro Alonso Journal: Diabetes Res Clin Pract Date: 2015-11-10 Impact factor: 5.602
Authors: John P Bentley; Folkert W Asselbergs; Christopher S Coffey; Patricia R Hebert; Jason H Moore; Hans L Hillege; Wiek H van Gilst Journal: PLoS One Date: 2010-09-15 Impact factor: 3.240